Improving ovarian cancer diagnosis in primary care
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial is looking at how doctors can better use the CA125 blood test to find ovarian cancer earlier. If you are being tested for ovarian cancer in primary care, this study might help improve how future patients are diagnosed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman being checked by your primary care doctor (GP) for possible ovarian cancer.
- You have had a blood test called CA125 (a common test for ovarian cancer) as part of your regular care.
- You do not have symptoms that could be ovarian cancer but weren't tested for it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a blood test called CA-125, along with other markers and checkups, can detect ovarian cancer early. It’s for women considered low risk who will do regular blood tests and possibly a vaginal ultrasound if results suggest it.
This trial tests a new blood-based test (OCS) that looks for tiny particles from tumor cells to watch for cancer returning after initial treatment. It is for women with ovarian cancer whose CA125 levels were normal before starting treatment.
This study looks at whether a blood test (MRD) can predict how well treatment works for ovarian cancer patients who do not have high CA125 levels, helping doctors choose better therapies.
This trial checks whether a “liquid biopsy,” a blood test, can help doctors tell apart different causes of a suspicious pelvic/ovarian mass and help with early detection. It may help avoid uncertainty before surgery by adding test results from blood along with imaging and standard markers.
This study is testing a new blood test that may help detect ovarian cancer earlier. Researchers want to see if it can tell the difference between people with ovarian cancer and those without it.
This study is testing a new blood test (called the EARLY panel) to see how well it can detect ovarian cancer in postmenopausal women aged 50–74. It aims to find out if the test is accurate and practical for routine screening.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.